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a b s t r a c t
Antiseizure medications (ASM) may contribute to adverse fetal outcomes in pregnant women with epilepsy (WWE). Folate processing (Methylenetetrahydrofolate reductase, MTHFR) gene abnormalities are
common in women with epilepsy and depression. L-methylfolate supplements may bypass MTHFR deficiencies, yet their use in WWE during gestation or on fetal development is not well studied. We examine
pregnancy histories of three WWE who supplemented with either folate or L-methylfolate and methylcobalamin (methylated B12) during pregnancies. Their pregnancy outcomes improved with Lmethylfolate and methylcobalamin supplementation. L-methylfolate and methylcobalamin supplementation merits further study in WWE who have MTHFR mutations, fertility, recurrent miscarriage and
or depression histories.
Ó 2020 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction

43

Women with epilepsy (WWE) are more likely to have problems
with conception, gestation and delivery of normal infants [1]. In
addition, WWE remain at higher risk of mood dysfunction and
depression [2]. Medications that lower burdens of depression,
bipolar disorder and epilepsy may have teratogenic effects
[1,2,4]. How antiseizure medication (ASM) might alter teratogenicity remains incompletely understood, however, in recent work
ASM induction of de novo genetic variants is unlikely [5]. ASM or
mood stabilizing medications such as carbamazepine (CBZ) and
valproic acid (VPA) have been shown to increase risk of fetal neural
tube defects (NTD) including spina bifida [1,3]. CBZ and VPA may
include altered folate mechanisms, specifically decreases in levels
of 5-formyl- and 10-formyltetrahydrofolate, which in turn may
disrupt DNA methylation and histone acetylation pathways which
may then alter cell division and migration [3,6].
Folate supplementation of up to 4 mg during gestation remains
standard of care for WWE in the USA [1]. Use of folate supplements
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Abbreviations: WWE, women with epilepsy; MTHFR, Methylenetetrahydrofolate
reductase; ASM, Antiseizure medication; ASD, Autism spectrum disorder.
⇑ Corresponding author.
E-mail addresses: emlascar@uw.edu (E.M. Lascar), Michael.Doherty@swedish.
org (M.J. Doherty).

from pre-conception to delivery decreases the odds ratio of NTD
development from 1.6 (95% CI 0.8–3.1) to 1.2 (95% CI 0.4–4.0)
[1,7–10], however folate mitigation of teratogenic effects due to
ASM have not been well documented [11,12]. Supplementary folate
in women taking CBZ and VPA for instance, does not decrease rates
of spina bifida [13]. Our epilepsy community remains focused on
ASM that have the lowest risk of use in pregnancy. If we have to
use a particularly teratogenic ASM in pregnancy such as VPA, the
strategies to limit fetal risk often jeopardize maternal seizure control, particularly if first trimester doses are lowered or risky and
quick substitution for less effective ASM occurs.
A potential risk factor for NTD can occur in folate pathways,
specifically,
a
polymorphism
that
codes
for
5,10methylenetetrahydrofolate reductase (MTHFR) [6,14]. This gene
makes folate bioavailable through methylation, permitting homocysteine to convert to methionine, a critical step for normal protein
synthesis. If MTHFR cannot methylate folate, common findings in
women who supplement with folic acid are elevations in serum
folate. Polymorphisms in the MTHFR gene at C677T for both the
homozygous (TT) and heterozygous (CT) genotypes are increased
in women with genetic generalized epilepsies when compared to
a woman without epilepsy, they are less well studied in women
with focal epilepsy [6,15]. Many women with generalized epilepsy
show superior control of their epilepsy when using VPA yet as a
community we try to avoid this drug in women of reproductive

https://doi.org/10.1016/j.ebr.2020.100419
2589-9864/Ó 2020 The Author(s). Published by Elsevier Inc.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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age due to side effect profiles including known teratogenicity. VPA
teratogenicity may be further exacerbated in women who have
defects in their MTHFR pathways [6].
Dietary folate, combined with dietary vitamin B12 are both
required in converting homocysteine to methionine and ultimately
lead to protein synthesis. [16] When these pathways do not function efficiently, homocysteine may elevate; hyperhomocysteinema
in pregnancy and in neonates may correlate with worse fetal outcomes. [16,17] Additional risks of folate pathways not functioning
well occur in the setting of limited bioavailable vitamin B12. [17]
5-methyltetrahydrofolate may be available as L-methylfolate
and is used in the USA for the treatment of depression [18,19].
The supplement has few known adverse effects and bypasses
MTHFR gene pathways, in essence becoming bioavailable when
gene efficiency is otherwise compromised. In patients with MTHFR
gene defects, data suggests prenatal supplementation with Lmethylfolate is more successful at increasing bioavailable folate
concentrations than unmethylated folic acid [20]. Furthermore,
infertility-based supplementation of methylated folates in women
and men with C677T MTHFR mutations may help with successful
conceptions and gestations [20].
Somewhat remarkably, whether methylated versions of folate
and vitamin B12 (methylcobalamin) taken by WWE helps avoid
depression, seizure, fertility, or adverse fetal outcomes like spina
bifida during pregnancy remains unknown. In this observational
report we document pregnancy, seizure and mood histories with
and without L-methylfolate or methylcobalamin for three women
with epilepsy with known MTHFR mutations.

113

2. Case reports

114

126

After informed consent patients were interviewed regarding
pregnancy, conception, miscarriage, mood and child developmental histories. Data are summarized on Table 1. No statistical testing
was performed. Key findings include pregnancy outcomes on varied supplement or medication doses. Standardized practice models
of adjusting antiseizure medication doses through serum drug
levels checked every 6 weeks during gestation as were referrals
to high risk Maternal Fetal Medicine specialists for surveillance
ultrasounds during gestations and peri-delivery care. If available,
homocysteine and folate levels are documented, these were not
serially surveyed. Seizures did not occur during any of the successful pregnancies, nor were they thought to be causative of any of the
miscarriages.
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3. Discussion

128

3.1. Notes on cases
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Patients one and two adopted methylated folate and methylcobalamin/injected B-12 supplementation after recurrent miscarriage or conception failures. We have no way of proving if these
two supplements helped with subsequent successful pregnancies
and deliveries, though successful pregnancies and deliveries suggested benefit. Importantly we did not see adverse outcomes. Particularly notable is the gestation failure for patient one’s fourth
pregnancy, which occurred on methylated folate though off of vitamin B12 injection therapies. All of the successful pregnancies
occurred while on methylated folate and either injected or methylated B12 supplements in addition to standard prenatal multivitamin supplements.
Patient three’s use of L-methylfolate therapies proved fundamental to her desire to even pursue pregnancy. Specifically, prior
to her L-methylfolate supplementation, she was recurrently treated with electroconvulsive therapies for refractory depression
2

and had not considered pregnancy. With L-methylfolate success
in treating her depression, she no longer required ECT, and both
her
mood and epilepsy remained
controlled
during
pregnancy and postpartum.

145

3.2. Limitations

149

This study has a small sample size, and as such miscarriage
rates may be no different than chance. Folate and homocysteine
levels were not serially surveyed in either the mothers or children,
the children remain young at time of writing, and without neuropsychological assessment. Similarly, mood batteries in the mothers pre and post methylated folate or methylcobalamin
supplementation were not done.
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3.3. Risks of folic acid and B12 elevations in pregnancy

157

Limited data exists on risks of elevated folate during pregnancy.
One study documents a U-shaped risk of third-trimester B12 and
folate levels in mothers with a risk of autism spectrum disorders
(ASD) in their offspring when levels are either low or very high
[21]. Rhagavan et al. found no risk of maternal folate and MTHFR
genotype status on ASD outcomes. Their study did not look at
cohort use during gestation of methylated vs non-methylated versions of B12 and/or folate.
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3.4. Implications

166

Many patients with genetic generalized epilepsies remain controlled on VPA, including during pregnancy [1]. Women on VPA
therapies during pregnancy have the highest risk of adverse fetal
outcomes [1]. Given MTHFR mutations are common in women
with generalized epilepsy, should they wish to conceive and if they
have to remain on VPA, pharmacogenetic targeting and preconception and pregnancy supplementation with L-methylfolate and
methylcobalamin if MTHFR defects are present should be studied
[19]. Similarly, women who were switched off of VPA preconception due to teratogenic concerns, that went on to have
recurrent fetal loss or conception failures, should also be considered candidates for a similar workup and therapy approach.
Regardless of a generalized epilepsy diagnosis, our study suggests women with a variety of ofepilepsy classifications with/without mood disorders with recurrent conception failures, irrespective
of medication profiles, could be screened for MTHFR mutations and
if abnormal, consider supplementation with both methylcobalamin and L-methyfolate. We have not found homocysteine levels
useful, nor folate levels practical in screening. Folate is often elevated in patients with MTHFR defects on supplemental folate and
may be falsely reassuring. Those patients, however, merit formal
study. Specifically with outcomes looking at safety, seizure controls, dosage of methylated vitamins, gestation success, incidence
of neonatal stroke or hypoxic ischemic issues, use of supplements
during breast feeding, incidence of spina bifida along with longer
term neonatal and neurodevelopmental outcomes, including ASD.
In addition, measurements of depression preconception, during
gestation, and post-partum could also be checked.
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4. Conclusion

195

After either recurrent fertility setbacks or depression in prior
pregnancies, three WWE with known MTHFR mutations had successful
pregnancies
when
supplementing
with
Lmethylfolate and methylated folate or methylcobalamin. Fetal
and maternal risks of exposure to methylated vitamins are not well
known. Prospective studies of methylated folate and methylcobal-
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Table 1

Age of
epilepsy
onset

Epilepsy
diagnosis

History of
Miscarriage

Pregnancy history

Medications during
successful
pregnancy

MTHFR genotype,
homocysteine,
folate, and B12
levels (if known)

Psychiatric
comorbidities

Status of
children’s
developmental
milestones

Patient
1

7

Generalized
onset,
motor, tonic
clonic

Third pregnancy at
36 via vaginal
delivery resulted in
a healthy boy. She
was seizure-free
throughout
pregnancy. Fifth
pregnancy at : age
39, 39 week csection and.
seizure-free
throughout
pregnancy.

Methylcobalamin
B12 oral or
parenteral B12
injections.
Levetiracetam 1500
bid, L-methylfolate
7.5 mg daily, and
prenatal vitamins
daily

Homozygous for
the C677T
mutation.
Homocysteine level
6 umol/L (prior to
L-methylfolate),
folate l> 20 ng/ml
(i.e. elevated)
tested when not on
methylfolate,
vitamin b12
699.3 pg/ml
(normal)

History of major
depressive disorder
and postpartum
depression after
her first child while
on L-methylfolate
and
methylcobalamin
and levetiracetam.
This occurred in the
setting of sleeping
poorly and
breastfeeding. No
depression after
her second child
while on lmethylfolate and
methylcobalamin.
She was switched
from levetiracetam
to valproic acid
postpartum.

Normal
development
for both
children now
age 8 and age 5

Patient
2

4

Focal
epilepsy
with
impaired
awareness
seizures

Normal for
both children
at age
4 months and
age 29 months

Focal
epilepsy
with focal
impaired
awareness
seizures

Cholecalciferol
(vitamin D3)
2000 IU dailyLmethylfolate 5 mg
daily,
methylcobalamin
B12 5 mg daily,
levetiracetam
1500 mg bid,
prenatal vitamins,
and zonisamide
200 mg daily
Methylcobalamain
B12 100 mcg,
sertraline 25 mg
daily, Lmethylfolate 15 mg
daily, vitamin D2
(ergocalciferol),
prenatal vitamins,
quetiapine 400 mg
daily, lamotrigine
500 mg AM and
400 mg PM

Postpartum
depression after
her second child
though reported
getting better.

28

Seccond pregnancy
at 34 via c-section
at 38 weeks
gestation. Seizurefree throughout
pregnancy. Third
pregnancy at 36
and 40 week
gestation via csection. Seizurefree throughout
pregnancy
First pregnancy:
uncomplicated
vaginal delivery
age 33 at 38 weeks
gestation. Seizurefree through
pregnancy.

Heterozygous
C667T mutation
and A1298C.
Homocysteine
normal at 6.4 umol/
L (pre Lmethylfolate),
folate > 19.9 ng/mL
(elevated) in
second pregnancy.

Patient
3

First, second and
fourth pregnancies
age 33, 34,38; all
first trimester
miscarriages
occurred on
prenatal vitamins
with additional
folate and
leveitracetam. No
methylated folate
or
methylcobalamin
for pregnancies 1
and 2; At age 38:
miscarriage while
on L-methylfolate
but not also taking
methylcobalamin.
Missed the B12
shot in the month
prior to
miscarriage.
First pregnancy,
age 32, first
trimester
miscarriage after
1 year of attempted
conception. No Lmethylfolate or
methylcobalamin
but she was on
folate,
levetiracetam and
zonisamide
N/A

Homozygous
C677T mutation,
homocysteine
normal at 11.4
umol/L (pre-Lmethylfolate)

Bipolar I disorder,
history of
depression, prior to
L-methylfolate
supplementation
with recurrent
electroconvulsive
therapy. This , was
not required again
after Lmethylfolate add.
edN No postpartum
worsening of
depression and she
continues to work
with psychiatrist.

Normal at age
40 months,
speech therapy
though all
other language
measures
normal or
above average.
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amin in WWE with/without mood disorders and known MTHFR
mutations and infertility or recurrent fetal loss, or females administered folate altering ASM such as VPA during pregnancy are
warranted.
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